Introduction
Atrial fibrillation (AF) and chronic heart failure have been described as the two epidemics of cardiovascular disease of the 21 st century. 1 The prevalence of AF increases with advancing age and is also associated with severity of heart failure reaching almost 50% in New York Heart Association (NYHA) class IV. [2] [3] [4] [5] [6] The prognostic impact of AF on hospitalization for heart failure and mortality remains, however, uncertain. 4, [7] [8] [9] [10] [11] [12] Beta-blockers are recommended as routine treatment in stable chronic heart failure in order to improve survival and reduce hospital admissions for heart failure. 13 Although it is generally assumed that the effects of beta-blockade in AF are similar to those in sinus rhythm, no clear advantageous effects of beta-blockade in heart failure patients with AF have been demonstrated so far. [14] [15] [16] In a substudy of the Cardiac Insufficiency Bisoprolol Study (CIBIS) II trial bisoprolol had no effect in patients with heart failure and AF. 14 study. 15, 16 These trials were, however, restricted to younger patients with low ejection fraction, whereas the additional prognostic influence of AF in heart failure appears to be most evident in heart failure with a preserved ejection fraction. 11, 17 Furthermore, the potential benefits of beta-blockers may differ between heart failure patients with a preserved as compared with an impaired ejection fraction. 18 In the present prespecified subanalysis of the Study of Effects of
Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With
Heart Failure (SENIORS) 19, 20 trial, we investigated the effects of nebivolol in elderly patients with heart failure and co-existing AF in the total group and in groups stratified by ejection fraction.
Methods
The methods and main results of the SENIORS trial have been published previously. 19, 20 In brief, SENIORS was a prospective, multi-center, multinational, double blind, placebo controlled, randomized, clinical trial comparing nebivolol with placebo in elderly patients with heart failure on optimal standard therapy. The first patient was included in September 2000, the last
Abstract Aims
Beneficial effects of beta-blockade remain unclear in heart failure patients who have atrial fibrillation (AF), especially in the elderly. We evaluated the effect of nebivolol on cardiovascular outcomes in elderly patients with heart failure and AF.
Methods and Results
The SENIORS trial showed an overall benefit of nebivolol compared with placebo in 2128 heart failure patients >70 years of age. At baseline AF was present in 738 (34.7%) patients. The primary outcome was all-cause mortality or cardiovascular hospitalizations. After 21 months the cumulative incidence of the primary outcome was significantly more common in patients with AF compared with those with sinus rhythm (38.5% vs. 30 
Conclusion
Nebivolol failed to improve outcomes in elderly patients with stable heart failure and co-existing AF, irrespective of LVEF. Furthermore, in patients with AF outcome was comparable between patients with preserved and impaired LVEF.
CHAPTER 5

Definition of atrial fibrillation
Patients were classified as AF when there was AF on the baseline electrocardiogram or if AF was documented in their medical history. Further information on duration of AF nor on the type of AF (paroxysmal, persistent, or permanent) was known.
Statistical methods
Baseline descriptive statistics are presented as mean ± standard deviation or median (range) for continuous variables and counts with percentages for categorical variables. Differences between groups were evaluated by the The primary outcome was a composite of all-cause mortality or cardiovascular hospitalizations and secondary outcomes were all-cause mortality, the composite of all-cause mortality or hospital admission for heart failure, and sudden cardiac death (all time to first event). All reported deaths and hospital admissions were referred to the independent Clinical Events Review Committee, blinded to treatment. Baseline ejection fraction was measured by echocardiography in 94%, nuclear imaging in 4%, and magnetic resonance imaging in 2% of patients. 21 During the first four months of followup patients were closely monitored as medication was carefully titrated. Target dose of nebivolol was 10 mg or the maximum tolerated dose for the individual patient. 19 For the duration of the maintenance phase it was advised to maintain the dose on the same individual dose of the study drug until the end of the follow-up period. During the titration phase patients were required to attend study visits at 1-2 weeks intervals. In this phase they were seen at least 5 times. Maximum period of drug titration was 16 weeks and the minimum 4 weeks. During the maintenance period, the first visit took place after 16 weeks after randomization, the second visit after 6 months and thereafter in intervals of 3 months until the 30 months visit which was also the end of study visit.
Results Patients
A physical examination was performed, changes in concomitant medication
were documented and an electrocardiogram was performed at each follow-up visit. After 6, 9, 12, 15, 24 and 30 months of follow-up blood samples were taken to assess liver and renal function and plasma glucose. 19 and sinus rhythm are shown in Table 1 . Patients with AF were older, had a higher NYHA classification for heart failure, and less often coronary artery disease or diabetes. The heart rate at baseline in the AF group was 83±16 beats per minute. The nebivolol and placebo groups were well balanced in patients with AF (Table 2) as well in those with sinus rhythm (data not shown).
Furthermore, dosages of nebivolol were equal between both groups.
Influence of atrial fibrillation on primary outcome
A total of 284 patients (38.5%) in the AF group and 423 patients (30.4%) in the sinus rhythm group reached the primary outcome of all-cause mortality or cardiovascular hospitalization (Figure 1, p<0 .001). There was no significant difference in all-cause mortality between both groups, 139 (18.8%) patients with AF versus 222 patients (16.0%) with sinus rhythm at baseline (figure 1).
Heart rate difference by nebivolol
In patients with AF randomized to nebivolol , the heart rates at baseline and the end end of follow-up was 82.9±15.8 and 71.8±14.5 b.p.m., respectively (mean heart rate reduction of 10.9 b.p.m., p<0.001). In the placebo group heart rates were 83.4±16.2 and 80.6±16.4 b.p.m. at baseline and end of follow up, respectively (mean heart rate reduction of 2.4 beats per minute, p=0.02). 
Influence of ejection fraction on outcome
Ejection fraction did not influence primary outcome irrespective of whether they had AF at baseline or not (Table 4 ). In patients with sinus rhythm and an ejection fraction of ≤ 35%, the primary 
Nebivolol in preserved and impaired ejection fraction
Influence of nebivolol on outcome in patients with atrial fibrillation
Kaplan-Meier curves for the primary outcome in patients with AF treated with nebivolol versus placebo are shown in Figure 2 . The cumulative incidence of the primary outcome was 37.1% (n=134) in the nebivolol and 39.8% (n=150) 
Discussion
Principal findings
In this large sample of representative elderly patients with heart failure we found that the beneficial effect of nebivolol appeared to be attenuated in patients with AF relative to patients with sinus rhythm.
This effect was observed irrespective of baseline ejection fraction. Furthermore, our analysis demonstrates that ejection fraction had no apparent influence on outcome in patients with AF.
Influence of atrial fibrillation on heart failure outcome
The influence of AF on prognosis in patients with heart failure is still not fully elucidated. 7, 10, 11, 22 Several studies reported that AF was associated with significantly increased mortality, although after adjustment for other covariates AF not always independently predicted mortality. 7, 10 Our study showed that patients with AF were at higher risk for the combined endpoint. Table 3 . Primary and main secondary outcomes in patients with atrial fibrillation and sinus rhythm. CI = Confidence interval. CHAPTER 5 Nevibolol as compared to placebo did not improve exercise capacity, possibly due to impaired chronotropic response during exercise. Data on the number of patients in AF, unfortunately, were not provided. Finally, patients with AF less often have underlying ischemic heart disease. Possibly, beta-blockers act differently in ischemic versus non-ischemic heart failure.
Notwithstanding the present findings, beta-blockade remains indicated in AF patients. 31, 32 In contrast to the recommendations in the heart failure guidelines which state that beta-blockers are recommended in all heart failure patients in order to reduce morbidity and mortality, in AF beta-blockers are recommended for rate control in order to reduce AF-related symptoms, but not to improve prognosis. 31, 33 As such, beta-blockers are frontline therapy in patients with AF and heart failure.
Heart failure with preserved or impaired ejection fraction
We were not able to demonstrate a difference in outcome between patients with a preserved and an impaired ejection fraction in SENIORS, regardless of underlying rhythm. In the main CHARM trial patients with an impaired ejection fraction were at a higher risk of mortality and heart failure hospitalizations.
However, a subanalysis of CHARM showed that the presence of AF as an adverse prognostic indicator was of a greater magnitude in those with preserved ejection fraction. 11, 34 Consistent with this subanalysis, a recently published study showed that AF was independently related to death or heart failure hospitalization in heart failure patients with preserved ejection fraction. 17 
Study limitations
Several limitations of the present study should be addressed. First, this was a post hoc analysis of the SENIORS trial and therefore not specifically designed nor powered to investigate the effect of nebivolol in elderly patients with heart failure and AF. Although the results are consistent with previous subanalyses, they should be seen in that perspective. Secondly, AF specific information was limited as they were classified based on baseline electrocardiogram. Further information on duration of AF nor on the type of AF (paroxysmal, persistent, or permanent) was known. This may have led to an underestimation of the AF group as some could have had sinus rhythm during the baseline electrocardiogram but having (episodes of) AF during follow up. predominantly in NYHA class II-III with mean ejection fraction of 28%. This study observed no relative risk reduction in patients with AF in contrast to patients in sinus rhythm. 16 The present study included 738 AF patients mostly NYHA class II-III patients, 77 years of age with a mean ejection fraction of 36%. Comparably, we also observed an attenuated effect of beta-blockade on all-cause mortality and cardiovascular hospitalizations in patients with AF. Furthermore, we demonstrated this effect not only in patients with an impaired left ventricular systolic function but as well in patients with a preserved ejection fraction.
How can this different effect of beta-blockers between HF patients with AF and sinus rhythm be explained? First, heart rate reduction by betablocker therapy may be less effective in patients with AF than in those with sinus rhythm since the mode of action of beta-blockers is different during AF and sinus rhythm. During sinus rhythm, beta-blockers exert their heart-rate lowering effect by targeting the sinus node, whereas during AF their main site of action is the atrioventricular node. In the present analysis, however, we found a similar mean reduction in heart rate for patients with both AF and sinus rhythm with comparable dosages of nebivolol. Second, it may well be that patients with AF and heart failure benefit from a slightly higher heart rate as compared to patients in sinus rhythm. AF patients in our study had a baseline (i.e. before start of beta-blocker therapy) heart rate of 83 beats per minute. After institution of nebivolol an average reduction in heart rate occurred of 11 beats per minute, leading to a mean heart rate of 72 beats per minute. 20, 21 In the above mentioned studies, comparable heart rate reductions in AF patients with bisoprolol, carvedilol and metoprolol, respectively, were achieved. [14] [15] [16] In contrast, placebo did not reduce heart rates below 80 beats per minute. Thus, achieving low heart rates, i.e. strict rate control, may not be appropriate in patients with AF, which, is in agreement with the recently published Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II (RACE II) study. [25] [26] [27] [28] This may be explained by a loss of the atrial kick and the irregularity in ventricular response during AF, implying that patients with AF may need higher heart rates to maintain a similar cardiac output, possibly even more so during heart failure. 29 Of interest and in line with our findings are recent observations of beta-blocker therapy in patients with heart failure and a preserved ejection fraction. 30 
